In the premiere episode of "Longevity," Rubenstein explores the ongoing obesity crisis in America, examining its longstanding impact and the latest medical advancements aimed at addressing it, most notably the development of GLP-1s. He also delves into the question of whether weight-loss drugs offer a lasting solution.

In the premiere episode of "Longevity," Rubenstein explores the ongoing obesity crisis in America, examining its longstanding impact and the latest medical advancements aimed at addressing it, most notably the development of GLP-1s. He also delves into the question of whether weight-loss drugs offer a lasting solution.

In the premiere episode of "Longevity," Rubenstein explores the ongoing obesity crisis in America, examining its longstanding impact and the latest medical advancements aimed at addressing it, most notably the development of GLP-1s. He also delves into the question of whether weight-loss drugs offer a lasting solution.

In the second episode of this four-part series, Rubenstein delved into the breakthroughs in cancer detection and treatment, how artificial intelligence could transform prevention and early diagnosis, why cancer rates are rising among young adults, the role of mRNA vaccines in preventing and treating future cancers and the urgent challenges of health disparities and access to care.

In the second episode of this four-part series, Rubenstein delved into the breakthroughs in cancer detection and treatment, how artificial intelligence could transform prevention and early diagnosis, why cancer rates are rising among young adults, the role of mRNA vaccines in preventing and treating future cancers and the urgent challenges of health disparities and access to care.

In the second episode of this four-part series, Rubenstein delved into the breakthroughs in cancer detection and treatment, how artificial intelligence could transform prevention and early diagnosis, why cancer rates are rising among young adults, the role of mRNA vaccines in preventing and treating future cancers and the urgent challenges of health disparities and access to care.

In this episode of Longevity with David Rubenstein, we explore the cutting-edge neuroscience of aging and Alzheimer's - from the first subtle signs of memory loss to breakthrough drugs that could slow or even prevent cognitive decline. Rubenstein speaks with leading experts: Dr. Richard Isaacson, Dr. Maria Carrillo, Dr. Vivek Murthy, and Bloomberg?s Robert Langreth to uncover how science, lifestyle and technology are transforming our understanding of brain health. This episode also examines the economic impact of dementia, including the costs to patients, caregivers, and healthcare systems, and how pharmaceutical companies are investing in the next generation of Alzheimer?s treatments.

In this episode of Longevity with David Rubenstein, we explore the cutting-edge neuroscience of aging and Alzheimer's - from the first subtle signs of memory loss to breakthrough drugs that could slow or even prevent cognitive decline. Rubenstein speaks with leading experts: Dr. Richard Isaacson, Dr. Maria Carrillo, Dr. Vivek Murthy, and Bloomberg?s Robert Langreth to uncover how science, lifestyle and technology are transforming our understanding of brain health. This episode also examines the economic impact of dementia, including the costs to patients, caregivers, and healthcare systems, and how pharmaceutical companies are investing in the next generation of Alzheimer?s treatments.

In this episode of Longevity with David Rubenstein, we explore the cutting-edge neuroscience of aging and Alzheimer's - from the first subtle signs of memory loss to breakthrough drugs that could slow or even prevent cognitive decline. Rubenstein speaks with leading experts: Dr. Richard Isaacson, Dr. Maria Carrillo, Dr. Vivek Murthy, and Bloomberg?s Robert Langreth to uncover how science, lifestyle and technology are transforming our understanding of brain health. This episode also examines the economic impact of dementia, including the costs to patients, caregivers, and healthcare systems, and how pharmaceutical companies are investing in the next generation of Alzheimer?s treatments.

We're living longer than ever before - but are we living better? In the final episode of this four-part series, David Rubenstein explores the science of aging; from groundbreaking research on longevity to why lifestyle matters more than genetics and how meaningful relationships can add years to our lives. Rubenstein speaks with leading scientists and researchers in the field and uncovers what it truly takes to live not just a long life, but a healthy and fulfilling one.

We're living longer than ever before - but are we living better? In the final episode of this four-part series, David Rubenstein explores the science of aging; from groundbreaking research on longevity to why lifestyle matters more than genetics and how meaningful relationships can add years to our lives. Rubenstein speaks with leading scientists and researchers in the field and uncovers what it truly takes to live not just a long life, but a healthy and fulfilling one.

We're living longer than ever before - but are we living better? In the final episode of this four-part series, David Rubenstein explores the science of aging; from groundbreaking research on longevity to why lifestyle matters more than genetics and how meaningful relationships can add years to our lives. Rubenstein speaks with leading scientists and researchers in the field and uncovers what it truly takes to live not just a long life, but a healthy and fulfilling one.